Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to share pricing for the bonus plan re-investment:
- Share price: 1483 pence per Ordinary share.
- ADR price: $46.35 per share.
Material Changes
The filing reports an increase in notional interests in Ordinary shares and ADRs for several executives following the re-investment of dividends paid on January 5, 2012. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details the mechanics of the deferred bonus plan, noting that notional dividends will be paid out based on the percentage of holdings vesting after a three-year measurement period.
Important Facts for Investors
- Transaction Type: Notification of share acquisitions by directors and senior management under a deferred bonus plan.
- Participants: Sir Andrew Witty, Mr S M Bicknell, Mrs D P Connelly, Mr D S Redfern, Dr M M Slaoui, Ms C Thomas, Mr D E Troy, and Dr P J T Vallance.
- Acquisition Method: Shares were acquired through both personal contributions and matching company contributions.
- Valuation Date: Transactions were executed at a price of 1483 pence per share on January 9, 2012.
- Scope: This filing does not contain financial results or operational updates for the company.